<DOC>
	<DOCNO>NCT02134899</DOCNO>
	<brief_summary>The investigator multicenter randomize open-labelled study investigate efficacy everolimus base immunosuppression reduce total native kidney volume kidney recipient autosomal dominant polycystic kidney disease compare calcineurin inhibitor-based immunosuppression .</brief_summary>
	<brief_title>The Efficacy Everolimus Reducing Total Native Kidney Volume Polycystic Kidney Disease Transplanted Recipients</brief_title>
	<detailed_description>Kidney graft recipient receive fir kidney graft ( 6 month 5 year post-transplantation ) randomize 1:1 receive everolimus base immunosuppression ( association steroid mycophenolate mofetil ) continue calcineurin inhibitor-based immunosuppression regimen . The primary objective reduction total native kidney volume 2-years treatment period .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney , Autosomal Dominant</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>age 18 75 yearsold recipient first kidney graft 6 month 5 year ago stable eGFR 30 ml/min/1,73m2 contraception female recipient avoid pregnancy valid health Insurance study period sign informed consent obtain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Autosomal dominant polycystic kidney disease</keyword>
	<keyword>cyst</keyword>
	<keyword>kidney</keyword>
	<keyword>liver</keyword>
	<keyword>kidney transplantation</keyword>
	<keyword>IF/TA</keyword>
	<keyword>fibrosis</keyword>
	<keyword>DSA</keyword>
	<keyword>mTOR inhibitor</keyword>
	<keyword>calcineurin inhibitor</keyword>
</DOC>